VanEck Associates
CLBT icon

VanEck Associates’s Cellebrite CLBT Stock Holding History

VanEck Associates’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
75,550
+21,834
+41% +$289K ﹤0.01% 1121
2026
Q1 		$740K Buy
53,716
+7,743
+17% +$117K ﹤0.01% 1125
2025
Q4 		$829K Sell
45,973
-574
-1% -$10.3K ﹤0.01% 1100
2025
Q3 		$863K Sell
46,547
-3,000
-6% -$47.1K ﹤0.01% 1110
2025
Q2 		$793K Buy
49,547
+14,111
+40% +$252K ﹤0.01% 1094
2025
Q1 		$689K Buy
35,436
+6,448
+22% +$136K ﹤0.01% 1101
2024
Q4 		$639K Buy
+28,988
New +$558K ﹤0.01% 1104

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

VanEck Associates's CLBT Position: Q2 2026 in Review

VanEck Associates increased its Cellebrite (CLBT) stake by 41% in Q2 2026, buying an estimated $289K and bringing the position to 75,550 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

VanEck Associates first reported a position in CLBT in Q4 2024 and has held it in 7 quarters since. 201 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • VanEck Associates held 75,550 shares of Cellebrite worth $1.1M as of Q2 2026.
  • VanEck Associates bought 21,834 Cellebrite shares in Q2 2026, an estimated $289K.
  • Cellebrite made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #1121 holding.
  • VanEck Associates first reported a position in Cellebrite in Q4 2024 and has held it in 7 quarters since.
  • 201 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.